Domov › Množni mielom › Ohio › Cincinnati
Klinične študije za Množni mielom v Cincinnati, OH
17 študij za Množni mielom išče udeležence na lokacijah v Cincinnati in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Vključevanje udeležencevFaza 3
- Research Site, Cincinnati
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 3
- The Christ Hospital, Cincinnati
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Vključevanje udeležencevFaza 3
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Vključevanje udeležencevFaza 2
- University of Cincinnati Medical Center, Cincinnati
- West Chester Hospital, West Chester · 15 mi stran
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Vključevanje udeležencevFaza 3
- University of Cincinnati Medical Center, Cincinnati
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 2
- Oncology Hematology Care, Cincinnati
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Vključevanje udeležencevFaza 3
- TriHealth Cancer and Blood Institute, Cincinnati
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Vključevanje udeležencevFaza 3
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- in še 4
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Vključevanje udeležencevFaza 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- in še 1
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Vključevanje udeležencevFaza 3
- Research Site, Cincinnati
- Research Site, Montgomery · 11 mi stran
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Vključevanje udeležencevFaza 1/2
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Vključevanje udeležencevFaza 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- in še 2
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Vključevanje udeležencevFaza 3
- University of Cincinnati, Cincinnati
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Vključevanje udeležencevFaza 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Vključevanje udeležencevFaza 2
- Oncology Hematology Care, Cincinnati
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- Oncology Hematology Care, Inc, Cincinnati
Študije za Množni mielom v drugih mestih
- New York City, NY60 študij
- Boston, MA42 študij
- Atlanta, GA41 študij
- Houston, TX38 študij
- Durham, NC37 študij
- Nashville, TN32 študij
- Denver, CO27 študij
- Rochester, MN24 študij
- St. Louis, MO24 študij
- Columbus, OH24 študij
- Baldwin Park, CA23 študij
- Chicago, IL22 študij
Druge študije v Cincinnati
- Nemalicelični pljučni rak35 študij
- Rak (vse vrste)27 študij
- Rak dojke25 študij
- Srčno popuščanje24 študij
- Kolorektalni rak21 študij
- Akutna mieločna levkemija20 študij
- Metastatski rak20 študij
- Rak jajčnikov19 študij
- Rak pljuč19 študij
- Debelost19 študij
- Rak prostate18 študij
- Melanom17 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.